FTC settles with Express Scripts to lower insulin costs

Federal regulators and the FTC reached a settlement with Express Scripts requiring the PBM to stop favoring high-list-price drugs tied to larger rebates, charge patient copays based on net rather than list prices, expand an insulin cap to $25/month for most members, adopt a cost-plus pharmacy payment model, and repatriate a major purchasing office from Switzerland to the U.S. The changes — subject to a 30-day public comment period — are intended to lower patient drug costs and stabilize community pharmacy revenue but could reduce PBM rebate revenue and press margins across Express Scripts and peers, with officials projecting billions in patient savings over the next decade.

Analysis

Market structure: The settlement shifts economic rents away from PBMs toward payors, pharmacies and patients — expect mid-single-digit percentage-point compression in PBM gross margins (3–7% of EBITDA) over 12–36 months as rebate-driven economics unwind. Winners: community and regional pharmacies (more predictable cost+fee revenue), employers and high-volume drugmakers (higher net-price transparency); Losers: vertically integrated PBM units and rebate-dependent manufacturers whose list-price strategies are penalized.

Risk assessment: Tail risks include aggressive industry-wide remediations (multi-$bn restitution) or coordinated antitrust suits that force accelerated contract rewrites — low-probability but could knock 10–30% off PBM/insurer equity value in a stressed window. Timing: immediate (30-day public comment), short-term (90–180 days for final orders and contract re-pricing), long-term (1–3 years for structural supply-chain/contract redesign). Hidden dependency: employer plan contract clauses and pharma rebate contracts may delay flow-through of savings.

Trade implications: Favor exposure to retail pharmacy and wholesalers that capture margin stability (6–18 month horizon); be selectively short PBM/insurer PBM units until fee-through economics are re-established. Use option structures to cap risk around approval points (30–90 days) and size positions to 1–3% portfolio exposure per thesis. Monitor market reaction at each insurer’s next quarterly guide for accelerants.

Contrarian angles: Consensus underestimates how fast smaller pharmacies can scale share if reimbursement stabilizes — a 5–10% market-share pivot among independent pharmacists is plausible inside 18 months, creating asymmetric upside for retailers/wholesalers. Also, PBMs may offset rebate losses by raising admin fees to plan sponsors, which could preserve PBM cash flow but shift costs to employers — watch employer renewal pricing as an early signal.

Key Decisions for Investors

• Establish a 1–2% notional short position in Cigna (CI) via a 3–6 month put spread to limit capital at risk; thesis: Express Scripts settlement implies 3–7% EBITDA pressure for PBM units if adopted industry-wide — increase allocation if FTC brings similar actions against other PBMs within 90 days.
• Establish a 1.5–3% long position in Walgreens Boots Alliance (WBA) equity (or 12-month call options sized equivalently) with a 6–18 month horizon; rationale: more stable, fee-based pharmacy economics and volume upside from insulin affordability programs should lift retail pharmacy EBITDA margins by low-double-digits percentage points versus current expectations.
• Initiate a 1–2% long position in McKesson (MCK) or other wholesale distributors (12-month) to capture upside from domesticized purchasing and higher volume flows; prefer cash bonds or equity to avoid excessive option decay.
• Enter a hedged pair trade: long WBA (2%) / short CI (1.5%) to express relative rotation from PBM-centric insurers to retail pharmacy exposure; rebalance after the 30-day public comment period or insurer earnings that cite PBM margin impacts.
• Buy 3–5% notional of 2–3 year protection on PBM credit risk (CDS or corporate bond puts on CI/UNH) as insurance against a worst-case multibillion remediation scenario; liquidate if regulatory filings over next 90 days show no escalation.